In vitro evaluation of ganaplacide/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance

• Published in: Journal of antimicrobial chemotherapy 2024-11, Vol.79 (11), p.2877-2886
• Main Authors: Manaranche, Jeanne, Laurent, Marion, Tressieres, Roxane, Nguyen, Michel, Salim, Maryam, Ouji, Manel, Reyser, Thibaud, Egwu, Chinedu O, Robert, Anne, Augereau, Jean-Michel, Benoit-Vical, Françoise, Paloque, Lucie
• Format: Article
• Language: English
• Subjects: Antimalarials - pharmacology; Artemisinins - pharmacology; Chemical Sciences; Drug Resistance - genetics; Ethanolamines - pharmacology; Ethanolamines - therapeutic use; Fluorenes - pharmacology; Human health and pathology; Humans; Infectious diseases; Life Sciences; Lumefantrine - pharmacology; Malaria, Falciparum - drug therapy; Malaria, Falciparum - parasitology; Medicinal Chemistry; Microbiology and Parasitology; Original Research; Parasitic Sensitivity Tests; Parasitology; Pharmaceutical sciences; Pharmacology; Plasmodium falciparum - drug effects; Plasmodium falciparum - genetics
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkae300

Ganaplacide, also known as KAF156, is among the new antimalarial drug candidates that have successfully reached Phase III clinical trials, and is proposed in combination with lumefantrine. This combination could replace the current front-line artemisinin-based combination therapies (ACTs) in case of Plasmodium falciparum resistance to both artemisinins and partner drugs. Indeed, the African continent, where the malaria burden is the highest, is currently experiencing worrying multiple emergences and spread of artemisinin resistance, which urges for the exploration of the antiparasitic properties of KAF156 in this context. The objectives of this work were firstly to evaluate the risk of cross-resistance between artemisinins and KAF156 alone, and in combination with lumefantrine, using a panel of artemisinin-resistant strains carrying different pfk13 mutations and markers of other antiplasmodial drug resistances; secondly to explore in vitro the relevance of combining KAF156 and lumefantrine with artemisinins, based on the model of triple ACTs. Our results highlighted that KAF156 activity was not impaired by mutations in pfk13, pfcrt, pfmdr1, pfmdr2, pfdhps and pfdhfr genes or by pfmdr1 amplification. Moreover, we demonstrated that KAF156 alone and in combination with lumefantrine was active against artemisinin-resistant parasites, including when they are quiescent. All these in vitro results evidence that multi-drug resistant parasites currently in circulation in the field might not affect KAF156 efficacy, and are encouraging signs for KAF156 use in a triple ACT to preserve the use of artemisinins for as long as possible.